ProCE Banner Activity

CME

Therapeutics Targeting TROP2 and HER3: Perspective on the Next Precision Treatment Advances Across Solid Tumors

Video

Get up to date with this on-demand webcast from a live symposium focused on the latest approaches in using TROP2- and HER3-targeted antibody‒drug conjugates for patients with breast, lung, and other solid tumors.

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Released: May 23, 2023

Expiration: May 22, 2024

No longer available for credit.

Share

Faculty

Rebecca S. Heist

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Funda Meric-Bernstam

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Paolo Tarantino

Paolo Tarantino, MD

Advanced Research Fellow
Harvard Medical School
Department of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This program is intended for pathologists, oncologists, pulmonologists, clinical investigators, and other healthcare professionals involved in the treatment of patients with solid tumors.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence and competence of learners in the optimal application of current and emerging data with TROP2 and HER3-targeting ADCs in solid tumors.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the biologic rationale for targeting TROP2 and features that differentiate the antibody–drug conjugates targeting TROP2

  • Select TROP2–targeting antibody–drug conjugate therapy or clinical trial enrollment for appropriate patients with NSCLC

  • Develop a treatment plan with agents targeting TROP2 in patients with TNBC or endocrine-resistant hormone receptor–positive/HER2-negative metastatic breast cancer 

  • Identify patients with locally advanced or metastatic NSCLC with an EGFR-activating mutation post TKI failure for enrollment on clinical trials investigating HER3-targeted agents

  • Construct a supportive care plan for patients experiencing treatment-related symptoms on treatment with a HER3- or TROP2‒targeted therapy

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Rebecca S. Heist, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts

Rebecca S. Heist, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, Claim Therapeutics, Daiichi Sankyo, EMD Serono, Lilly, Novartis, Regeneron, Sanofi; researcher (paid to institution): AbbVie, Agios, Corvus, Daichii Sankyo, Erasca, Lilly, Mirati, Novartis, Turning Point.

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Funda Meric-Bernstam, MD: researcher: Aileron, AstraZeneca, Bayer, Calithera, Curis, CytomX, Daiichi Sankyo, Debiopharm, eFFECTOR, Genentech, Guardant, Klus, Novartis, Puma, Taiho, Takeda; consultant: AbbVie, Aduro, Alkermes, AstraZeneca, Biovica, Black Diamond, Chugai, Daiichi Sankyo, Debiopharm, Ecor1, eFFECTOR, Eisai, F. Hoffmann-LaRoche, FogPharma, Genentech, GT Apeiron, Harbinger, IBM Watson, Immunomedics, Infinity, Inflection, Jackson, Karyopharm, Kolon, Lengo, Loxo, Menarini, Mersana, OnCusp, OrigiMed, PACT, Paralexel, Pfizer, Protai, Puma, Samsung, Sanofi, Seattle Genetics, Silverback, Spectrum, Tallac, Theratechnologies, Tyra, Xencor, Zentalis, Zymeworks.

Paolo Tarantino, MD

Advanced Research Fellow
Harvard Medical School
Department of Breast Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Paolo Tarantino, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Gilead, Lilly. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 23, 2023, through May 22, 2024:

1. Login or Sign Up for an account by clicking at the top of this page.
2. Read the target audience, learning objectives, and faculty disclosures.
3. View and study the content in its entirety.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.